Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ7716MR)

This product GTTS-WQ7716MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_002062.5
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	2740
UniProt ID	P43220

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7716MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ1246MR	IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	ABT-165
GTTS-WQ5634MR	IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CDP870
GTTS-WQ5898MR	IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	CIM 331
GTTS-WQ4591MR	IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	BMS-986004
GTTS-WQ2118MR	IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	Alb-IFNA2 R23 (608)
GTTS-WQ7106MR	IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	FE 999301
GTTS-WQ9434MR	IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	IPH-2201
GTTS-WQ1976MR	IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	AGS-15E

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST